Inhibikase Therapeutics (IKT) announced the appointment of veteran biopharma executive Timothy Pigot as the Company’s Chief Commercial and Strategy Officer. Most recently Pigot served as Chief Commercial Officer of Aerovate Therapeutics, where he led commercial planning and strategy for the Company’s therapeutic candidate in PAH.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKT: